Pharmaceutical

Granules India Ltd on Thursday said its arm Granules Pharmaceuticals, Inc has received tentative approval from the US health regulator for its generic amphetamine extended-release tablets indicated for treatment of attention deficit hyperactivity disorder, with eligibility of 180-day exclusivity. The tentative approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Amphetamine extended-release tablets in strengths of 5 mg, 10 mg, 15 mg, and 20 mg, Granules India Ltd said in a regulatory filing. These are the generic equivalent of DYANAVEL XR, it added. "The Granules ANDA has been determined to be eligible for 180-day exclusivity by the FDA, reinforcing its growing capabilities in developing and commercialising complex and differentiated generic products for the US market," the company said. The product is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and has an estimated market size of USD 41 ...

Granules India plans to raise up to ₹1,762 crore from promoter, and non-promoter groups through a mix of convertible warrants and preferential issue of equity shares.

Ilumya, a novel biologic treatment that selectively inhibits IL-23, has already established itself as a blockbuster drug internationally, with presence across 35 countries

AstraZeneca Pharma India and Sun Pharmaceutical Industries have formed an exclusive brand partnership to promote and distribute SZC for hyperkalaemia treatment under separate brands

Eli Lilly invests $1B in India as Mounjaro succeeds, Hyderabad site to boost global supply and innovation

Tata Capital Healthcare Fund II has deployed nearly all of its $130 million corpus, benefiting 8.3 million people and driving job creation and gender diversity across India's healthcare ecosystem

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark's Novo Nordisk, over a bid for Metsera that Novo announced Thursday. Novo said it planned to buy Metsera in a deal that could be worth up to $9 billion, and Metsera said the offer appeared to be superior to Pfizer's bid, which was announced in September. Metsera Inc has no products on the market, but it is developing potential oral and injectable treatments. That includes some potential treatments that could target lucrative fields for obesity and diabetes. Novo already has the treatments Wegovy and Ozempic on the market in those respective categories. Pfizer said the offer from Novo cannot be considered superior to its bid because it carries significant regulatory risk that makes it unlikely to be completed. Pfizer, which ended development of a potential pill to

Sharvil Patel takes over as President of IPA from Samir Mehta, with Glenn Saldanha appointed Vice President, as the industry navigates reforms and global challenges

The Trump administration has clarified that while these tariffs might not be enforced immediately, they are still in play and can be implemented in the near future

Vector Consulting Group study finds pharma firms spend up to ₹75 cr annually on IT systems, but 70% of digital projects fail due to adoption gaps and poor execution

Till 11:32 AM; as many as a combined 130 million equity shares representing 34 per cent of total equity of Sigachi changed hands on the NSE (112 million shares) and BSE (18 million shares).

GST Council meet outcome: GST on various medical apparatus and devices used for medical, surgical, dental or veterinary usage has been reduced to 5% from 12%

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes

The global market for weight-loss drugs is estimated at $100 billion by the end of the decade

Laurus stock price outlook: Given the higher-margin profile of CDMO and operating leverage as new manufacturing assets ramp, brokerage firms expect sustained margin expansion.

Patel Chem Specialities, a manufacturer of starch-based pharmaceutical excipients, on Thursday fixed the price at Rs 82-84 per share for its Rs 58.80 crore initial public offering (IPO). The IPO will open on July 25 and conclude on July 29. The shares of the company will be listed on BSE's SME platform, Patel Chem Specialities said in a statement. The public issue is entirely a fresh issue of up to 70 lakh equity shares. Proceeds from the issue will be utilised to set up a plant at Indrad, Mahesana, for manufacturing Croscarmellose Sodium (CCS), Sodium Starch Glycolate (SSG) Corn Starch Base & Potato Starch Base and Calcium Carboxymethylcellulose (CMC) and general corporate purposes. Incorporated in 2008, Patel Chem Specialities is engaged in the manufacturing and exporting of pharmaceutical excipients and specialty chemicals. As of FY25, the company has an installed production capacity of 7,200 MT per year, with a capacity utilisation rate of 89 per cent. "The IPO proceeds will

Donald Trump's plan to impose pharma tariffs could hit Indian drugmakers like Biocon, Lupin, and Sun Pharma, with new levies starting August 1

In the past six months, the Divis Labs stock has outperformed the market by surging 18 per cent, as against 1.4 per cent fall in the BSE Healthcare index and 7 per cent rise in the BSE Sensex.

BE to produce and commercialise Recbio's nine-valent HPV vaccine in India and global markets, including participation in UNICEF and PAHO tenders

Shift is expected to drive a sharp increase in generic drug launches, positioning Indian drugmakers for strong growth